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Age and severity of extrapyramidal signs have been consistently associated with incident dementia in Parkinson’s disease.
We evaluated the separate and combined effects of age and severity of extrapyramidal signs on the risk of incident
dementia in Parkinson’s disease in the setting of a population-based prospective cohort study. Age and the total Unified
Parkinson’s Disease Rating Scale motor score at baseline evaluation were dichotomized at the median. Four groups of
Parkinson’s disease patients were defined: younger age/low severity (reference), younger age/high severity, older age/low
severity, and older age/high severity. Risk ratios for incident dementia were calculated with Cox proportional hazards
models controlling for gender, education, ethnicity, and duration of Parkinson’s disease. Of 180 patients, 52 (28.9%)
became demented during a mean follow-up period of 3.6  2.2 years. The median age at baseline of the Parkinson’s
disease patients was 71.8 years (range, 38.5–95.9 years), and the median total Unified Parkinson’s Disease Rating Scale
motor score was 24 (range, 2–65). The group with older age/high severity had a significantly increased risk of incident
dementia (relative risk, 9.7; 95% confidence interval, 3.9–24.4) compared with the group with younger age/low severity
(reference), whereas the groups with older age/low severity (relative risk, 1.6; 95% confidence interval, 0.5–4.8) and
younger age/high severity (relative risk, 1.2; 95% confidence interval, 0.5–3.2) did not. These findings suggest that the
increased risk of incident dementia in Parkinson’s disease associated with age and severity of extrapyramidal signs is
related primarily to their combined effect rather than separate effects.
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Dementia complicates the course of idiopathic Parkin-
son’s disease (PD) in many patients. The development
of dementia in patients with PD limits standard phar-
macotherapy of PD,1 affects quality of life,2 contrib-
utes to caregiver distress,3 and has been associated with
nursing home placement.4 The development of demen-
tia also has been associated with reduced survival in
patients with PD.5–7 In community-based studies using
Diagnostic and Statistical Manual of Mental Disorders,
revised third edition (DSM-III-R)8 criteria, dementia is
present in approximately 20 to 40% of PD pa-
tients.9–13 Incidence rates of dementia in PD, esti-
mated in both hospital-based and community-based
studies using DSM-III-R criteria, range from 42.6 to
112.5 per 1,000 person-years of observation.12,14–18
Age and severity of extrapyramidal signs (EPSs) have
been consistently associated with incident dementia in
PD in longitudinal studies.12,15,17–21 Mayeux and col-
leages14 showed that age-specific incidence rates for de-
mentia in a clinic-based sample of PD increased with
age; the cumulative incidence of dementia reached
65% by age 85 years. In a population-based sample,
the same investigators found that the age-specific prev-
alence of dementia in PD ranged from 12.4% in the
group 50 to 59 years old to 68.7% in the group older
than 80 years old.10 The pathological basis of dementia
in PD has not been clearly established. Although some
studies suggest that the presence of concomitant Alz-
heimer’s disease (AD) cortical changes is causally re-
lated to dementia in PD,22–24 the correlation of sever-
ity of EPSs with intellectual deficits has been seen as
evidence in favor of the contribution of the subcortical
pathology characteristic of PD to the development of
dementia.25–27
No previous longitudinal study has investigated the
combined effect of age and severity of EPSs on the risk
of incident dementia in PD. Basing their statement on
cross-sectional studies of the influence of age at onset
of PD on neuropsychological performance,28–30
Dubois and colleages29 suggested that the cognitive
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disorder in the late-onset group might be related to “a
potentiation between the effect of aging and the effect
of PD-specific brain lesions.” We hypothesized that the
increased risk of dementia in PD associated with older
age and increased severity of EPSs was primarily related
to their combined effects. To test this hypothesis, we
evaluated the separate and combined effects of age and
severity of EPSs on the risk of incident dementia in
PD by using a prospective cohort design. We also eval-
uated the effect of age and severity of EPSs on the rel-
ative risk (RR) of incident dementia in PD compared
with the risk of dementia in a normal aging population
from the same community.
Patients and Methods
Patients and Procedures
A cohort of nondemented PD patients from the Washington
Heights–Inwood community in northern Manhattan in New
York City was followed up annually with neurological and
neuropsychological evaluations. The ascertainment procedure
and inclusion and exclusion criteria for the cohort have been
described previously.10 Patients were ascertained through the
development of a registry in the community for all individ-
uals considered to have PD living within four zip codes in
Washington Heights–Inwood. This registry included, but
was not limited to, all patients living in the community who
received their care at the Columbia Presbyterian Medical
Center. Patients were identified from many sources, includ-
ing admission and discharge lists from the hospital, lists from
various ambulatory care sites, and practitioners both in the
hospital and in the community.
Idiopathic PD was defined by established research crite-
ria.31–33 Patients with postencephalitic and drug-induced
parkinsonism or a Parkinson-plus syndrome were excluded,
as were patients who developed memory loss or dementia
before the motor manifestations of PD. In this study of in-
cident dementia in PD, of 319 patients with idiopathic PD,
105 considered to be demented at baseline evaluation were
excluded. Of 214 nondemented PD patients, 30 had no
follow-up visit, and 4 with signs or symptoms of stroke at
baseline were excluded, leaving 180 patients for this analysis.
The annual clinical evaluation included the Unified Par-
kinson’s Disease Rating Scale (UPDRS).34 The duration of
PD was defined as the time period between the first symp-
tom of PD as reported by the patient/informant and the
baseline evaluation. The neuropsychological battery consisted
of tests of verbal and nonverbal memory, orientation, visuo-
spatial ability, language, and abstract reasoning, and neuro-
psychological test scores were evaluated with a fixed para-
digm.35 Dementia was diagnosed according to the DSM-
III-R criteria, which require memory impairment and
impairment of abstract thinking, impaired judgment, distur-
bances of higher cortical function, or personality change, of
sufficient severity to interfere with social or occupational
functioning.8
For the second analysis, which was designed to calculate
RRs of dementia in PD compared with a normal aging pop-
ulation, we selected a random sample of 180 controls partic-
ipating in a longitudinal study of aging and dementia in the
same community.36 This control sample was frequency-
matched to the PD patients by age at baseline, gender, edu-
cation, and ethnicity as closely as possible. The annual neu-
ropsychological evaluation and the criteria for the diagnosis
of dementia for the controls were the same as for the PD
patients.35
Data Analysis
Age and total UPDRS motor score at baseline evaluation
were dichotomized at the median. We defined four PD
groups based on these two dichotomous variables: younger
age/low severity, younger age/high severity, older age/low se-
verity, and older age/high severity. The group with younger
age/low severity was used as the reference against which the
risk ratios for incident dementia of the other three groups
were calculated.
Each item of the motor examination (part III) of the UP-
DRS was rated from 0 (no impairment) to 4 (severe impair-
ment).34 The total UPDRS motor score (range, 0–100) was
calculated by the summing of 25 items of the UPDRS (part
III). In a previous analysis of the association of motor im-
pairment with incident dementia in PD,37 we divided the
total UPDRS motor score into two subscores because of the
clinical evidence that some motor signs (speech, gait, pos-
ture, and balance impairment) are relatively refractory to
L-dopa therapy, especially in middle and late stages of the
disease, whereas others (tremor, rigidity, and bradykinesia)
are not.38–41 Subscore A, representing predominantly dopa-
minergic deficiency, includes facial expression, tremor at rest,
action or postural tremor, rigidity, body bradykinesia and
hypokinesia, hand movement, rapid alternating movements
of hands, and leg agility (range, 0–80). Subscore B, repre-
senting predominantly nondopaminergic deficiency, includes
speech, rising from a chair, posture, gait, and postural stabil-
ity (range, 0–20). When these two subscores were substi-
tuted for the total UPDRS motor score in the analysis, sub-
score B, but not subscore A, was significantly associated with
incident dementia in PD.37 Therefore, in this study we re-
peated the analyses using severity of motor impairment ac-
cording to subscores A and B as the measures of disease se-
verity.
Baseline characteristics of patients were compared with
Student t tests and one-way analysis of variance for contin-
uous variables and 2 tests for categorical variables. Post hoc
pairwise comparisons for overall differences in the one-way
analysis of variance were performed with Tukey-Kramer
multiple-comparisons test. We used Cox proportional haz-
ards models42 to calculate risk ratios for incident dementia in
PD patients stratified by age and severity of EPSs (reference
group: younger age/low severity). The duration of follow-up
from the baseline until the diagnosis of dementia (or until
the last visit for those patients who did not become de-
mented) was used as the timing variable in the Cox models.
These analyses were adjusted for gender, education, ethnic-
ity, and duration of PD. When the risk ratios were estimated
for incident dementia in PD patients compared with con-
trols, the age at time of development of dementia (or at the
last visit for those patients and controls who did not become
demented) was used as the timing variable in the Cox mod-
els, with adjustments made for gender, education, and eth-
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nicity. The proportional hazards assumption of the Cox
models was checked by an examination of the martingale re-
siduals.43
Results
Of 180 PD patients, 52 (28.9%) became demented
during a mean follow-up period of 3.6  2.2 years
(median, 3.1; range, 0.5–8.2 years), whereas of 180
controls, 19 (10.6%) became demented during a mean
follow-up period of 3.9  2.0 years (median, 3.5;
range, 1.0–9.5 years). Baseline demographic and clini-
cal characteristics of PD patients and controls are
shown in Table 1. PD patients were not significantly
different from controls in terms of education, gender,
ethnicity, and primary language. However, age at base-
line was slightly but significantly higher in controls
(73.8  6.3 vs 71.0  10.3 years, p  0.002). PD
patients with incident dementia were significantly older
and had fewer years of education than PD patients
without incident dementia. At baseline, the total UP-
DRS motor score and subscores A and B were signifi-
cantly higher in PD patients with incident dementia
than in PD patients without incident dementia.
The median age at baseline of the PD patients was
71.8 years (range, 38.5–95.9 years), and the median
total UPDRS motor score was 24 (range, 2–65). We
created, using these median values, dichotomous vari-
ables for younger and older ages (72 and 72 years)
and low and high severities of EPSs (24 and 24).
The demographic and clinical characteristics of the
four groups defined by these two dichotomous vari-
ables are shown in Table 2. There were statistically sig-
nificant differences among the four groups in educa-
tion, ethnicity, primary language, duration of PD, and
estrogen replacement therapy. No statistically signifi-
cant differences were observed for gender, medication
use, depressive symptoms, having at least one apoli-
poprotein E-ε4 allele, ever or currently smoking, or
stroke signs or symptoms during follow-up. Approxi-
mately 60% of the older age/high severity group and
15 to 25% of the other three groups developed demen-
tia during follow-up.
The risk ratios (95% confidence intervals [CIs]) for
incident dementia in PD patients stratified by age and
severity of EPSs are shown in Table 3. The group with
older age/high severity had a significantly increased risk
of incident dementia (RR, 9.7; 95% CI, 3.9–24.4)
compared with the group with younger age/low sever-
ity (reference). The groups with older age/low severity
(RR, 1.6; 95% CI, 0.5–4.8) and younger age/high se-
verity (RR, 1.2; 95% CI, 0.5–3.2) did not have a sig-
nificantly increased risk of incident dementia compared
with the reference. When we repeated this analysis in
females, adjusting for estrogen replacement therapy, in













Age (yr) 74.6 (8.2) 69.5 (10.7)a 71.0 (10.3) 73.8 (6.3)b
Education (yr) 9.4 (4.6) 11.8 (4.7)a 11.1 (4.8) 10.2 (4.9)
Gender (% male) 55.8 42.2 46.1 43.9
Ethnicity (%)
White non-Hispanic 55.8 55.5 55.6 53.3
Black non-Hispanic 7.7 9.4 8.9 10.6
Hispanic 36.5 35.2 35.6 36.1
Primary language (% English) 52.9 65.4 61.8 64.2
Age at onset of PD (yr) 67.3 (10.3) 63.6 (12.8) 64.7 (12.2) NA
Duration of PD (yr) 7.3 (5.8) 5.9 (7.2) 6.3 (6.9) NA
Total UPDRS motor score (range, 0–100) 32.0 (13.6) 22.2 (11.4)a 25.0 (12.8) NA
Subscore A (range, 0–80) 23.4 (11.7) 17.1 (9.2)a 18.9 (10.4) NA
Subscore B (range, 0–20) 8.6 (3.2) 5.1 (3.5)a 6.1 (3.7) NA
Use of L-dopa (%) 71.2 73.4 72.8 NA
Use of dopaminergic agonists (%) 34.0 25.8 28.1 NA
Use of anticholinergics (%) 17.6 15.2 15.9 NA
Use of selegiline (%) 5.8 11.7 10.0 NA
L-dopa dosage (mg/day) 326.7 (325.3) 364.2 (373.6) 354.1 (360.6) NA
Values are given as mean (standard deviation) or percentage. Total: 178 for language, 177 for total UPDRS motor score and subscores A and
B, 178 for use of dopaminergic agonists, 176 for use of anticholinergics, and 159 for L-dopa dosage.
ap  0.05, PD patients with incident dementia vs PD patients without incident dementia; bp  0.05, PD patients vs controls.
NA  not applicable; PD  Parkinson’s disease; UPDRS  Unified Parkinson’s Disease Rating Scale.
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addition to education, ethnicity, and disease duration,
results were similar.
The median subscore A was 18 (range, 0–53), and
the median subscore B was 6 (range, 0–18). Based on
these median values, two dichotomous variables for low
and high severities of EPSs according to subscore A
(18 and 18) and subscore B (6 and 6) were
created. When subscore A was used as the measure of
disease severity, only the group with older age/high se-
verity had a significantly increased risk of incident de-
mentia (RR, 9.3; 95% CI, 3.7–23.4) compared with
the group with younger age/low severity. In the analy-
sis using subscore B as the measure of disease severity,
both the groups with younger age/high severity (RR,
3.7; 95% CI, 1.3–10.3) and older age/high severity
(RR, 16.1; 95% CI, 6.0–43.0) had a significantly in-
creased risk of incident dementia compared with the
group with younger age/low severity (see Table 3).
Table 2. Demographic and Clinical Characteristics of 4 Groups of Parkinson’s Disease Patients (Total 177)
Stratified by Age and Severity of Extrapyramidal Signs as Measured by the Total Unified Parkinson’s Disease Rating











Agea (yr) 62.2 (8.5)b 63.7 (5.9)b 78.9 (5.4) 79.3 (4.7)
Education (yr)a 12.6 (4.4)b 9.7 (5.1) 12.5 (4.0)b 9.7 (4.7)
Gender (% male) 53.2 55.8 30.2 45.5
Ethnicity (%)a
White non-Hispanic 57.4 25.6 81.4 56.8
Black non-Hispanic 8.5 7.0 7.0 11.4
Hispanic 34.0 67.4 11.6 31.8
Primary language (% English)a 71.7 32.6 73.8 65.9
Age at onset of PDa (yr) 56.9 (9.6)b 56.7 (8.7)b 75.1 (6.5) 70.2 (11.4)
Duration of PD (yr)* 5.3 (4.4)b 6.9 (6.7) 3.9 (3.2)b 9.1 (10.2)
Total UPDRS motor score (range, 0–100)a 14.6 (6.5)b 34.7 (9.6) 16.1 (5.9)b 35.4 (9.9)
Use of L-dopa (%) 80.9 76.7 58.1 72.7
Use of dopaminergic agonists (%) 31.9 32.6 20.9 26.2
Use of anticholinergics (%) 19.6 23.8 14.0 7.1
Use of selegiline (%) 17.0 2.3 11.6 9.1
L-dopa dosage (mg/day) 420.6 (340.8) 428.5 (455.6) 212.8 (258.4) 321.6 (326.5)
Total 17-item HDRS score (range, 0–53) 5.7 (5.0) 5.9 (4.7) 6.0 (5.3) 6.7 (5.8)
Estrogen replacement therapy (%)a 30.4 22.2 6.7 4.0
At least one APOE-ε4 allele (%) 23.1 19.4 32.0 21.9
Ever smoking (%) 46.8 41.9 36.6 51.2
Current smoking (%) 4.3 4.7 7.3 4.7
Stroke signs or symptoms during follow-up (%) 10.6 16.3 9.3 13.6
Incident dementia (%)a 14.9 23.3 18.6 59.1
Values are given as mean (standard deviation) or percentage. Total: 175 for language, 175 for dopaminergic agonists, 173 for use of anticho-
linergics, 157 for L-dopa dosage, 151 for total HDRS score, 96 for estrogen replacement therapy, 132 for apolipoprotein E genotype, and 174
for ever and current smoking.
aOverall statistically significant (p  0.05) difference among the four groups (2 test for categorical variables and one-way analysis of variance
for continuous variables); bpairwise statistically significant difference (Tukey-Kramer multiple-comparisons test; p  0.05) compared with the
group with older age/high severity.
EPS  extrapyramidal sign; HDRS  Hamilton Depression Rating Scale; PD  Parkinson’s disease; UPDRS  Unified Parkinson’s Disease
Rating Scale.
Table 3. Risk Ratios for Incident Dementia in Parkinson’s Disease Patients Stratified by Age and Severity of Extrapyramidal Signsa
Age/Severity of EPSs Total UPDRS Motor Score (95% CI) Subscore A (95% CI) Subscore B (95% CI)
Younger/low (reference) 1 1 1
Younger/high 1.2 (0.5–3.2) 1.0 (0.4–2.7) 3.7 (1.3–10.3)
Older/low 1.6 (0.5–4.8) 1.4 (0.5–4.3) 2.1 (0.6–8.0)
Older/high 9.7 (3.9–24.4) 9.3 (3.7–23.4) 16.1 (6.0–43.0)
aCox proportional hazards model with duration of follow-up until dementia as the timing variable, adjusting for gender, education, ethnicity,
and disease duration.
CI  confidence interval; EPS  extrapyramidal sign; PD  Parkinson’s disease; UPDRS  Unified Parkinson’s Disease Rating Scale.
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Risk ratios (95% CI) for incident dementia in PD
compared with controls, as well as estimates of the in-
cidence rates (95% CI) of dementia in PD patients and
controls per 1,000 person-years of observation, are
shown in Table 4. The risk ratio for incident dementia
in the PD cohort compared with controls was 3.7
(95% CI, 2.1–6.3), with adjustments made for gender,
education, and ethnicity (Fig, A). When we performed
this analysis stratifying by age at baseline (72 and
72 years), the RR of incident dementia in PD com-
pared with controls was higher for the younger group
(RR, 5.6; 95% CI, 2.3–13.6) than for the older group
(RR, 3.5; 95% CI, 1.7–6.9). In the analysis stratified
by gender, males (RR, 5.5; 95% CI, 2.4–12.7) had a
higher RR of incident dementia in PD compared with
controls than females (RR, 2.5; 95% CI, 1.2–5.3).
Table 5 shows the risk ratios (95% CI) for incident
dementia in PD compared with controls according to
severity of EPSs. The group with high EPS severity had
a higher risk of incident dementia than the group with
low EPS severity, but both groups had a significantly
increased risk compared with controls (see Fig, B). We
also repeated these analyses stratifying by gender. Males
with low EPS severity and females with high EPS se-
verity had a threefold significantly increased risk,
whereas males with high EPS severity had a sevenfold
significantly increased risk of incident dementia in PD
compared with controls (see Table 5).
Discussion
Combined Effect of Age and Extrapyramidal
Sign Severity on the Risk of Dementia in
Parkinson’s Disease
The main aim of this study was to evaluate the separate
and combined effects of age and severity of EPSs on
the risk of incident dementia in PD. Compared with
PD patients with younger age/low severity of EPSs,
only the group with older age/high severity had a sig-
Fig. Cox proportional hazards model plots of the cumulative incidence of dementia in (A) Parkinson’s disease (PD) patients and
controls and (B) PD patients with high and low severity of extrapyramidal signs, as measured by the total Unified Parkinson’s Dis-
ease Rating Scale motor score, and controls.
Table 4. Incidence Rates of Dementia for Controls and
Parkinson’s Disease Patients and Risk Ratios for Incident







Total (n  360)
Control (n180) 27.0 (15.0–39.0) 1 (reference)
PD (n  180) 79.9 (59.1–100.7) 3.7 (2.1–6.3)
Age at baseline (yr)
72 (n  183)
Control (n  93) 16.8 (4.5–29.2) 1 (reference)
PD (n  90) 44.3 (23.7–64.9) 5.6 (2.3–13.6)
72 (n  177)
Control (n  87) 41.8 (18.7–65.0) 1 (reference)
PD (n  90) 130.9 (90.4–171.3) 3.5 (1.7–6.9)
Gender
F (n  198)
Control (n  101) 29.5 (13.0–45.9) 1 (reference)
PD (n  97) 65.7 (39.7–91.6) 2.5 (1.2–5.3)
M (n  162)
Control (n  79) 23.7 (6.3–41.0) 1 (reference)
PD (n  83) 96.4 (63.1–129.8) 5.5 (2.4–12.7)
aCox proportional hazards model with age at dementia as the timing
variable; analyses for the total PD patients and controls and strati-
fied by age at baseline performed adjusting for gender, education,
and ethnicity; analyses stratified by gender performed adjusting for
education and ethnicity.
CI  confidence interval; PD  Parkinson’s disease.
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nificantly increased risk of incident dementia in PD.
This finding suggests that the increase in risk of inci-
dent dementia in PD associated with age and severity
of EPSs is related primarily to their combined effects.
The combined effect of age and severity of EPSs on
the risk of dementia in PD has possible implications
for the understanding of the biological substrate of de-
mentia in PD. Our findings suggest that dementia in
PD may be caused by a PD and age-related patholog-
ical process, rather than concomitant AD. In principle,
superimposed AD might account for the increased risk
of dementia in PD compared with a normal aging pop-
ulation because a shared genetic susceptibility to both
PD and AD would increase the risk of dementia in PD
patients because of concomitant AD. In fact, we pre-
viously reported a threefold increased risk of AD in
siblings of demented PD patients compared with sib-
lings of controls, supporting this possibility.44 The
present data cannot address the question of whether
there is a shared susceptibility to PD and AD. How-
ever, the finding that the older age/high severity group,
but not the older age/low severity group, is at a signif-
icantly increased risk of dementia compared with the
younger age/low severity group supports a role of the
pathological process intrinsic to PD in the develop-
ment of dementia. This is consistent with recent neu-
ropathological studies using -synuclein immunostain-
ing that found a stronger association of the presence of
Lewy bodies in cortical areas than AD cortical changes
with dementia in PD.45–47
It has been proposed that PD patients with older age
at onset have increased motor disability because of
more widespread subcortical involvement including
nondopaminergic structures.48–50 In a previous study,
we suggested that gait and postural impairment (sub-
score B), especially late in the disease course, resulted
from a combined effect of the disease and aging process
in nondopaminergic brainstem structures (ie, locus cer-
uleus and pedunculopontine nucleus).37 In this study,
using subscore A as the measure of disease severity, we
found that only the group with older age/high severity
had a significantly increased risk of dementia. In the
analysis using subscore B as the measure of disease se-
verity, both the group with younger age/high severity
and the group with older age/high severity had a sig-
nificantly increased risk of dementia (see Table 3). This
is consistent with the previous finding that subscore B,
representing predominantly nondopaminergic defi-
ciency, is more closely related to dementia in PD.37 It
also suggests that subscore A may represent a more spe-
cific measure of the disease process.
Incidence of Dementia in Parkinson’s Disease
Compared with Controls
The risk ratio for incident dementia in PD compared
with controls was 3.7 (95% CI, 2.1–6.3). In previous
studies, estimates of the RR of incident dementia in
PD compared with controls have ranged from 1.7-fold
to 5.9-fold.12,18,51,52 In a previous analysis of a 2-year
follow-up of 140 patients,12 we reported a lower risk
ratio of incident dementia in PD compared with con-
trols (RR, 1.7; 95% CI, 1.1–2.7) than in this study
because of a higher incidence rate of dementia in the
control group than in this study. A total of 27 PD
patients became demented during the 2-year period,
resulting in an incidence rate of 112.5 per 1,000 per-
son years, whereas 87 of 572 controls became de-
mented during the same period (approximately
80/1,000 person years). However, in a recent study in
the same community over a 7-year period,53 the inci-
dence rate of AD in the elderly (30/1,000 person years)
was close to that observed in the control sample in this
study.
Breteler and colleages52 evaluated the risk of devel-
oping dementia in PD patients aged 50 to 75 years
compared with a control group in a study based on
Dutch nationwide morbidity registers. Because the age-
specific risk differences or attributive risks (excess ab-
solute risk with respect to the reference group) were
constant in 5-year age groups, these authors suggested
that the increase in the incidence of dementia in PD
with age was due to the increasing background risk of
dementia. In our study, the risk differences did increase
with increasing age, as can be estimated from the dif-
ferences in the incidence rates of dementia in PD and
controls stratified by age at baseline (see Table 4) and
from the curves of cumulative incidence of dementia in
PD and controls (see Fig, A). The differences in the
Table 5. Risk Ratios for Incident Dementia in PD as Compared with Controls According to Severity of EPSs as Measured by the
Total UPDRS Motor Score, for the Total PD Patients and Controls and Stratified by Gendera
Total (n  357) (95% CI) F (n  196) (95% CI) M (n  161) (95% CI)
Control (reference) 1 1 1
PD low severity 2.4 (1.2–4.9) 1.9 (0.7–5.0) 3.0 (1.0–8.7)
PD high severity 4.6 (2.6–8.1) 3.0 (1.3–6.8) 7.2 (3.1–17.2)
aCox proportional hazards model with age at dementia as the timing variable; analyses for the total PD patients and controls performed
adjusting for gender, education, and ethnicity; analyses stratified by gender performed adjusting for education and ethnicity.
CI  confidence interval; EPS  extrapyramidal sign; PD  Parkinson’s disease; UPDRS  Unified Parkinson’s Disease Rating Scale.
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age distributions between studies may have influenced
the findings; the 75-year upper limit of age at entry in
the cohort in the study by Breteler and colleagues con-
trasted with the median age at baseline of 71.8 years
(range, 38.5–95.9 years) in our PD cohort. Increases in
the risk difference of dementia in PD compared with
controls with age may be observed only in cohorts in-
cluding patients older than 75 years.
The risk ratio for incident dementia in PD com-
pared with controls was higher for males than females
(see Tables 4 and 5). Many studies have reported a
higher frequency of dementia in PD in
males,17,52,54–56 but this association has not been dem-
onstrated in other studies.10,18,20,57 To our knowledge,
no study has reported a higher frequency of dementia
in females with PD.
Methodological Considerations
There are some methodological limitations to this
study. The median age at baseline of our PD cohort
was 71.8 years, and the group with older age included
patients aged 72 years and older. Our results to a great
extent may depend on the overall old age of patients in
this cohort and may not be applicable to a younger
cohort of PD patients. Although age at baseline evalu-
ation rather than age at onset of PD was used in our
analysis, the analysis adjusted for the duration of PD
from onset to baseline evaluation. Moreover, these two
age variables were highly correlated (r  0.83, p 
0.001), and results were similar when the analysis was
repeated after the groups with younger and older ages
were defined by the median age at onset of PD (65.7
years; range, 25.8–87.5 years). Most patients were tak-
ing L-dopa (72.8%), 28.1% were taking a dopaminer-
gic agonist, and 15.9% were taking anticholinergics
when evaluated. However, there were no statistically
significant differences in the use of medications, or
L-dopa dosage, among the four groups of PD patients
(see Table 2), and we did not observe a relationship
between medication regimen at baseline (eg, L-dopa
alone vs L-dopa plus dopaminergic agonist and/or an-
ticholinergics) and the development of dementia (data
not shown).
In the analysis of the incidence of dementia in PD
patients compared with a normal aging population, the
control group was not completely comparable because
it was selected from an aging study including patients
60 years and older, whereas 15% of our PD cohort
were younger than 60 years at baseline. However, this
control group was representative of the risk of demen-
tia in the population of patients because controls were
drawn from the same community, were submitted to
similar annual clinical and neuropsychological evalua-
tions, were diagnosed as demented according to the
same criteria, and were closely matched to our PD co-
hort in gender, education, and ethnicity.
In summary, PD patients were three to four times as
likely as controls to develop dementia in this study,
and the risk was highest for men with severe EPSs.
Our findings suggest that the association of age and
EPS severity with incident dementia in PD consistently
demonstrated in previous studies is related primarily to
their combined effect rather than separate effects.
This study was supported by federal grants (AG10963, K.M., H.M.;
AG07232, K.M., Y.S.; RR00645, K.M.; and NS36630, K.M., E.L.,
G.L.) and the Parkinson’s Disease Foundation (611406, K.M., Y.S.,
H.M.).
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